Parthenolide inhibits proliferation of vascular smooth muscle cells through induction of G0/G1 phase cell cycle arrest

Journal of Zhejiang University: Science B

Volumn 10, Issue 7, 2009, Pages 528-535

  Weng, Shao Xiang ^a   Sui, Mei Hua ^a,b   Chen, Shan ^a   Wang, Jian An ^a   Xu, Geng ^a   Ma, Ji ^a   Shan, Jiang ^a   Fang, Lu ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cell proliferation; Cyclooxygenase 2(Cox 2); I B ; p21; Parthenolide; Vascular smooth muscle cell (VSMC)

Indexed keywords

CYCLOOXYGENASE 2; DNA; I KAPPA B ALPHA; PARTHENOLIDE; PROTEIN P21; PROTEIN P27; THYMIDINE DERIVATIVE; TRITIUM;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL ISOLATION; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; FLOW CYTOMETRY; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REACTION TIME; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; G0 PHASE; G1 PHASE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; RATS; RATS, SPRAGUE-DAWLEY; SESQUITERPENES;

RATTUS; TANACETUM PARTHENIUM;

EID: 67650590959     PISSN: 16731581     EISSN: 18621783     Source Type: Journal    
DOI: 10.1631/jzus.B0820351     Document Type: Article

References (34)

1. Baeuerle, P.A., Henkel, T., 1994. Function and activation of NF-kappaB in the immune system. Annu. Rev. Immunol., 12(1):141-179. [doi:10.1146/ annurev.immunol.12.1.141]
2. Bishop-Bailey, D., Hla, T., Mitchell, J.A., 1999. Cyclooxygenase-2 in vascular smooth muscle. Int. J. Mol. Med., 3(1):41-48.
3. Brown, K., Park, S., Kanno, T., Franzoso, G., Siebenlist, U., 1993. Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha. Proc. Natl. Acad. Sci. USA, 90(6):2532-2536. [doi:10.1073/pnas.90.6.2532]
4. Chen, F., Castranova, V., Shi, X., Demers, L.M., 1999. New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Clin. Chem., 45(1):7-17.
5. Collins, T., Cybulsky, M.I., 2001. NF-kappaB: Pivotal mediator or innocent bystander in atherogenesis? J. Clin. Invest., 107(3):255-264. [doi:10.1172/JCI10373]
6. Dubois, R.N., Abramson, S.B., Crofford, L., Gupta, R.A., Simon, L.S., van de Putte, L.B., Lipsky, P.E., 1998. Cyclooxygenase in biology and disease. FASEB J., 12(12):1063-1073.
7. Gomez-Hernandez, A., Martin-Ventura, J.L., Sanchez-Galan, E., Vidal, C., Ortego, M., Blanco-Colio, L.M., Ortegan, L., Tunon, J., Egido, J., 2006. Overexpression of COX-2, prostaglandin E synthase-1 and prostaglandin E receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: Regulation by nuclear factor-kappaB. Atherosclerosis, 187(1):139-149. [doi:10.1016/j.atherosclerosis.2005.08.035]
8. Groenewegen, W.A., Heptinstall, S., 1990. A comparison of the effects of an extract of feverfew and parthenolide, a component of feverfew, on human platelet activity in-vitro. J. Pharm. Pharmacol., 42(8):553-557.
9. Hedin, U., Roy, J., Tran, P.K., 2004. Control of smooth muscle cell proliferation in vascular disease. Curr. Opin. Lipidol., 15(5):559-565. [doi:10.1097/00041433-200410000-00010]
10. Hehner, S.P., Heinrich, M., Bork, P.M., Vogt, M., Ratter, F., Lehmann, V., Schulze-Osthoff, K., Droge, W., Schmitz, M.L., 1998. Sesquiterpene lactones specifically inhibit activation of NF-kappaB by preventing the degradation of I kappa B-alpha and I kappa B-beta. J. Biol. Chem., 273(3):1288-1297. [doi:10.1074/jbc.273.3.1288]
11. Hehner, S.P., Hofmann, T.G., Droge, W., Schmitz, M.L., 1999. The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex. J. Immunol., 163(10):5617-5623.
12. Heinrich, M., Robles, M., West, J.E., Ortiz de Montellano, B.R., Rodriguez, E., 1998. Ethnopharmacology of Mexican asteraceae (Compositae). Annu. Rev. Pharmacol. Toxicol., 38(1):539-565. [doi:10.1146/annurev.pharmtox.38.1.539]
13. Hengst, L., Reed, S.I., 1998. Inhibitors of the Cip/Kip family. Curr. Top. Microbiol. Immunol., 227:25-41.
14. Knight, D.W., 1995. Feverfew: Chemistry and biological activity. Nat. Prod. Rep., 12(3):271-276. [doi:10.1039/np9951200271]
15. López-Franco, O., Hernández-Vargas, P., Ortiz-Muñoz, G., Sanjuán, G., Suzuki, Y., Ortega, L., Blanco, J., Egido, J., Gómez-Guerrero, C., 2006. Parthenolide modulates the NF-kappaB-mediated inflammatory responses in experimental atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 26(8):1864-1870. [doi:10.1161/01.ATV.0000229659.94020.53]
16. Maddika, S., Ande, S.R., Panigrahi, S., Paranjothy, T., Weglarczyk, K., Zuse, A., Eshraghi, M., Manda, K.D., Wiechec, E., Los, M., 2007. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug. Resist. Update, 10(1):13-29. [doi:10.1016/j.drup.2007.01.003]
17. Marnett, L.J., Rowlinson, S.W., Goodwin, D.C., Kalgutkar, A.S., Lanzo, C.A., 1999. Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. J. Biol. Chem., 274(33):22903-22906. [doi:10.1074/jbc.274.33.22903]
18. Moon, S.K., Cha, B.Y., Kim, C.H., 2004. ERK1/2 mediates TNF-alpha-induced matrix metalloproteinase-9 expression in human vascular smooth muscle cells via the regulation of NF-kappaB and AP-1: involvement of the ras dependent pathway. J. Cell Physiol., 198(3):417-427. [doi:10.1002/jcp.10435]
19. Nilsson, J., Ksiazek, T., Thyberg, J., 1983. Effects of colchicine on DNA synthesis, endocytosis and fine structure of cultivated arterial smooth muscle cells. Exp. Cell. Res., 143(2):367-375. [doi:10.1016/ 0014-4827(83)90063-0]
20. Oka, D., Nishimura, K., Shiba, M., Nakai, Y., Arai, Y., Nakayama, M., Takayama, H., Inoue, H., Okuyama, A., Nonomura, N., 2007. Sesquiterpene lactone parthenolide suppresses tumor growth in a xenograft model of renal cell carcinoma by inhibiting the activation of NF-kappaB. Int. J. Cancer, 120(12):2576-2581. [doi:10.1002/ijc.22570]
21. Pang, L., Holland, E., Knox, A.J., 1998. Role of cyclo-oxygenase-2 induction in interleukin-1beta induced attenuation of cultured human airway smooth muscle cell cyclic AMP generation in response to isoprenaline. Br. J. Pharmacol., 125(6):1320-1328. [doi:10.1038/ sj.bjp.0702193]
22. Parada-Turska, J., Paduch, R., Majdan, M., Kandefer-Szerszen, M., Rzeski, W., 2007. Antiproliferative activity of parthenolide against three human cancer cell lines and human umbilical vein endothelial cells. Pharmacol. Rep., 59(2):233-237.
23. Rivard, A., Andres, V., 2000. Vascular smooth muscle cell proliferation in the pathogenesis of atherosclerotic cardiovascular diseases. Histol. Histopathol., 15(2):557-571.
24. Ross, J.J., Arnason, J.T., Birnboim, H.C., 1999. Low concentrations of the feverfew component parthenolide inhibit in vitro growth of tumor lines in a cytostatic fashion. Planta Med., 65(2):126-129. [doi:10.1055/ s-1999-13972]
25. Shanmugam, R., Jayaprakasan, V., Gokmen-Polar, Y., Kelich, S., Miller, K.D., Yipschneider, M., Cheng, L., Bhat-Nakshatri, P., Sledge, G.W.Jr., Nakshatri, H., et al., 2006. Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model. Prostate, 66(14):1498-1511. [doi:10.1002/pros.20482]
26. Sheehan, M., Wong, H.R., Hake, P.W., Malhotra, V., O'Connor, M., Zingarelli, B., 2002. Parthenolide, an inhibitor of the nuclear factor-kappaB pathway, ameliorates cardiovascular derangement and outcome in endotoxic shock in rodents. Mol. Pharmacol., 61(5):953-963. [doi:10.1124/mol.61.5.953]
27. Smolinski, A.T., Pestka, J.J., 2005. Comparative effects of the herbal constituent parthenolide (Feverfew) on lipopolysaccharide-induced inflammatory gene expression in murine spleen and liver. J. Inflamm. (Lond)., 2(1):6. [doi:10.1186/1476-9255-2-6]
28. Spyridopoulos, I., Andres, V., 1998. Control of vascular smooth muscle and endothelial cell proliferation and its implication in cardiovascular disease. Front Biosci., 3(1):d269-d287.
29. Thyberg, J., Palmberg, L., Nilsson, J., Ksiazek, T., Sjolund, M., 1983. Phenotype modulation in primary cultures of arterial smooth muscle cells. On the role of platelet-derived growth factor. Differentiation, 25(2):156-167.
30. Tzeng, H.P., Yang, R.S., Ueng, T.H., Liu, S.H., 2007. Upregulation of cyclooxygenase-2 by motorcycle exhaust particulate-induced reactive oxygen species enhances rat vascular smooth muscle cell proliferation. Chem. Res. Toxicol., 20(8):1170-1176. [doi:10.1021/tx700084z]
31. Weissberg, P.L., Grainger, D.J., Shanahan, C.M., Metcalfe, J.C., 1993. Approaches to the development of selective inhibitors of vascular smooth muscle cell proliferation. Cardiovasc. Res., 27(7):1191-1198. [doi:10.1093/cvr/27.7.1191]
32. Wong, H.R., Menendez, I.Y., 1999. Sesquiterpene lactones inhibit inducible nitric oxide synthase gene expression in cultured rat aortic smooth muscle cells. Biochem. Biophys. Res. Commun., 262(2):375-380. [doi:10.1006/bbrc.1999.1207]
33. Young, W., Mahboubi, K., Haider, A., Li, I., Ferreri, N.R., 2000. Cyclooxygenase-2 is required for tumor necrosis factor-alpha- and angiotensin II-mediated proliferation of vascular smooth muscle cells. Circ. Res., 86(8):906-914.
34. Zingarelli, B., Hake, P.W., Denenberg, A., Wong, H.R., 2002. Sesquiterpene lactone parthenolide, an inhibitor of IkappaB kinase complex and nuclear factor-kappaB, exerts beneficial effects in myocardial reperfusion injury. Shock, 17(2):127-134. [doi:10.1097/ 00024382-200202000-00008]